Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 7/20 | 0.77 |
| ▸ | GSK3B | P49841 | 7/20 | 0.77 |
| ▸ | CDK1 | P06493 | 4/20 | 0.77 |
| ▸ | CDK2 | P24941 | 4/20 | 0.77 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.77 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.77 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.77 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.77 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.77 |
| ▸ | GSK3A | P49840 | 2/20 | 0.77 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.77 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.77 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371554 | 0.94 | GSK3B (0.76) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2381619 | 0.90 | CDK9 (0.79) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2401576 | 0.89 | GSK3B (0.74) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2401133 | 0.89 | GSK3B (0.74) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2380941 | 0.89 | CDK9 (0.77) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2370242 | 0.87 | CDK9 (0.86) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2401071 | 0.87 | CDK9 (1.00) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2370737 | 0.87 | CDK9 (1.00) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL2401067 | 0.87 | CDK9 (1.00) | CDK9GSK3BCDK1CDK2CDK3 | |
| SCHEMBL12317644 | 0.87 | CDK9 (1.00) | CDK9GSK3BCDK1CDK2CDK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| EP-2545037-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110612-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | CDK9 26/4885GSK3B 25/4885CDK1 1/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | CDK9 26/4885GSK3B 25/4885CDK1 1/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | CDK9 26/4885GSK3B 25/4885CDK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.